Orbital Leiomyosarcoma After Bilateral Retinoblastoma Treated With Chemotherapy And Radiotherapy

##plugins.themes.bootstrap3.article.main##

  •   Aoife Smyth

  •   Elizabeth M. McElnea

  •   Penelope McKelvie

  •   Alan McNab

Abstract

A 23-year old man presented with a swelling medially in his left orbit. He had had bilateral retinoblastoma as an infant and was treated with bilateral enucleation, chemotherapy and radiotherapy. Histological examination confirmed the lesion to be leiomyosarcoma. A genetic defect in the RB1 tumour suppressor gene underlies the development of hereditary retinoblastoma and renders patients at substantially increased risk of developing subsequent non-ocular malignancies including soft tissue sarcomas. This risk is enhanced by radiotherapy particularly if administered before the age of one year. Awareness, by both patients and healthcare professionals, of this risk of secondary malignancy, is extremely important. Identification and aggressive investigation of new symptoms and signs may allow for the earlier detection of secondary malignancy which may, in turn, improve outcomes.


Keywords: Leiomyosarcoma; Radiotherapy; Retinoblastoma

References

Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108(1):128-32.

Gatta G, Botta L. Childhood cancer survival in Europe: action is needed. Epidemiol Prev. 2013;37(6):363-6.

Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol. 2001;119(11):1699-704.

Dunkel IJ, Gerald WL, Rosenfield NS, Strong EW, Abramson DH, Ghavimi F. Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience. Med Pediatr Oncol. 1998;30(1):59-62.

Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272-9.

Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-7.

Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121-8.

Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828-48.

Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99(1):24-31.

Ryan RS1, Gee R, O'Connell JX, Harris AC, Munk PL. Leiomyosarcoma of the distal femur in a patient with a history of bilateral retinoblastoma: a case report and review of the literature. Skeletal Radiol. 2003;32(8):476-80.

Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32(29):3284-90.

Jenkinson HC, Winter DL, Marsden HB, Stovall MA, Stevens MC, Stiller CA et al. A study of soft tissue sarcomas after childhood cancer in Britain. Br J Cancer. 2007;97(5):695-9.

Meekins BB, Dutton JJ, Proia AD. Primary orbital leiomyosarcoma. A case report and review of the literature. Arch Ophthalmol. 1988;106(1):82-6.

Russell WO, Cohen J, Enzinger F, Hajdu SI, Heise H, Martin RG et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer. 1977;40(4):1562-70.

Nair AG, Kaliki S, Kamal S, Mishra DK, Vemuganti GK. Conjunctival Leiomyosarcoma: A Report of Two Cases. Orbit. 2015;34(5):274-8.

Jakobiec FA, Howard GM, Rosen M, Wolff M. Leiomyoma and leiomyosarcoma of the orbit. Am J Ophthalmol. 1975;80(6):1028-42.

Chaugule SS, Putambekar A, Gavade S, Deshpande R. Primary Orbital Leiomyosarcoma in an Adult Male. Ophthalmic Plast Reconstr Surg. 2019;35(2):e27-e29.

Padrón-Pérez N, Mascaró-Zamora F, Gutiérrez-Miguelez C. Can J Ophthalmol. 2013;48(4):65-7. Adjuvant pulse dose rate brachytherapy in a secondary leiomyosarcoma of the orbit.

Folberg R, Cleasby G, Flanagan JA, Spencer WH, Zimmerman LE. Orbital leiomyosarcoma after radiation therapy for bilateral retinoblastoma. Arch Ophthalmol. 1983;101(10):1562-5.

Klippenstein KA, Wesley RE, Glick AD. Orbital leiomyosarcoma after retinoblastoma. Ophthalmic Surg Lasers. 1999;30(7):579-83.

Mihara F, Gupta KL, Kartchner ZA, Kogutt MS, Robinson AE. Leiomyosarcoma after retinoblastoma radiotherapy. Radiat Med. 1991;9(5):183-4.

Font RL, Jurco S 3rd, Brechner RJ. Postradiation leiomyosarcoma of the orbit complicating bilateral retinoblastoma. Arch Ophthalmol. 1983;101(10):1557-61.

Tselis N, Karagiannis E, Kolotas C, Baghi M, Milickovic N, Zamboglou N. Image-guided interstitial high-dose-rate brachytherapy in the treatment of inoperable recurrent head and neck malignancies: An effective option of reirradiation. Head Neck. 2017;39(4):E61-E68.

Jakobiec FA, Howard GM, Rosen M, Wolff M. Leiomyoma and leiomyosarcoma of the orbit. Am J Ophthalmol. 1975;80(6):1028-42.

Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S. Leiomyosarcoma of the maxillary sinus. Med J Malaysia. 2009 Jun;64(2):174-5.

Wojno T, Tenzel RR, Nadji M. Orbital leiomyosarcoma. Arch Ophthalmol. 1983;101(10):1566-8.

Liu JC, Givi B, Wolden S, Kleinerman RA, Dunkel IJ, Lee N et al. Secondary skull base malignancies in survivors of retinoblastoma: the memorial sloan kettering cancer center experience. Skull Base. 2011;21(2):103-8.

Pendergrass TW, Davis S. Incidence of retinoblastoma in the United States. Arch Ophthalmol. 1980;98(7):1204-10.

Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol. 2009;93(1):24-7.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

How to Cite
Smyth, A., McElnea, E., McKelvie, P., & McNab, A. (2020). Orbital Leiomyosarcoma After Bilateral Retinoblastoma Treated With Chemotherapy And Radiotherapy. European Journal of Medical and Health Sciences, 2(3). https://doi.org/10.24018/ejmed.2020.2.3.321